NEW YORK, May 2, 2017 /PRNewswire/ --
Stock-Callers.com revisits the Biotechnology industry, a highly volatile and unpredictable space that serves the medical, agricultural, environmental, and industrial markets, among others. Equities under assessment are ContraVir Pharmaceuticals Inc. (NASDAQ: CTRV), Intra-Cellular Therapies Inc. (NASDAQ: ITCI), Nivalis Therapeutics Inc. (NASDAQ: NVLS), and OncoSec Medical Inc. (NASDAQ: ONCS). Register now and get full and free access to our downloadable research reports on these stocks at:
On Monday, shares in Edison, New Jersey headquartered ContraVir Pharmaceuticals Inc. recorded a trading volume of 1.39 million shares, which was above their three months average volume of 1.02 million shares. The stock ended at $0.83, declining 1.19% from the last trading session. The Company's shares are trading below their 200-day moving average by 43.45%. Furthermore, shares of ContraVir Pharma, which operates as a biopharmaceutical company focused on the development of antiviral drugs with a primary emphasis on the treatment of Hepatitis B virus (HBV) infections, have a Relative Strength Index (RSI) of 20.49.
On April 22nd, 2017, ContraVir Pharma presented data demonstrating the synergistic antiviral activity from the combination of its two investigational drugs for the treatment of hepatitis B viral infection: tenofovir exalidex (TXL™, formerly CMX157), a nucleotide reverse transcriptase inhibitor, and CRV431, a cyclophilin inhibitor. The data were presented in separate poster presentations at The International Liver Congress® 2017, the annual meeting of the European Association for the Study of the Liver in Amsterdam, The Netherlands. Access our complete research report on CTRV for free at:
New York headquartered Intra-Cellular Therapies Inc.'s stock finished yesterday's session 24.10% lower at $10.49. A total volume of 14.74 million shares was traded, which was above their three months average volume of 564,730 shares. The Company's shares are trading below their 50-day moving average by 26.27%. Furthermore, shares of Intra-Cellular Therapies, which engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson's and Alzheimer's disease, have an RSI of 28.23.
On May 01st, 2017, research firm Piper Jaffray downgraded the Company's stock rating from 'Overweight' to 'Neutral'. The complimentary research report on ITCI can be downloaded at:
At the close of trading on Monday, shares in Boulder, Colorado headquartered Nivalis Therapeutics Inc. saw a slight drop of 0.44%, ending the day at $2.25. The stock recorded a trading volume of 190,816 shares. The Company's shares have advanced 3.69% in the previous three months and 0.45% since the start of this year. The stock is trading 16.56% below its 50-day moving average. Moreover, shares of Nivalis Therapeutics, which focuses on the discovery and development of product candidates for patients with cystic fibrosis in the US, have an RSI of 34.72.
On April 18th, 2017, Nivalis Therapeutics and Alpine Immune Sciences, Inc., a privately held biotechnology company developing novel therapies using its next-generation immune system modulation platform, jointly announced they have entered into a definitive merger agreement under which the latter will merge with a wholly owned subsidiary of Nivalis in an all-stock transaction. The merger will result in a combined company with a novel protein-based discovery platform focused on inflammation and immuno-oncology. Register for free on Stock-Callers.com and get access to the latest PDF format report on NVLS at:
San Diego, California headquartered OncoSec Medical Inc.'s shares ended the day 1.74% lower at $1.13, with a total trading volume of 66,060 shares. The stock is trading 12.85% below its 50-day moving average. Shares of the Company, which designs, develops, and commercializes gene therapies, therapeutics, and proprietary medical approaches to stimulate and guide an anti-tumor immune response for the treatment of cancer in the US, have an RSI of 36.71. Download your free research report on ONCS at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44-330-808-3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA